Research programme: nicotinamide phosphoribosyltransferase inhibitors - AurigeneAlternative Names: NAMPT inhibitors - Aurigene
Latest Information Update: 17 May 2016
At a glance
- Originator Aurigene Discovery Technologies
- Class Small molecules
- Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer